Market Cap 419.86M
Revenue (ttm) 79.18M
Net Income (ttm) -64.72M
EPS (ttm) N/A
PE Ratio 20.98
Forward PE 20.17
Profit Margin -81.74%
Debt to Equity Ratio 0.00
Volume 289,260
Avg Vol 356,764
Day's Range N/A - N/A
Shares Out 20.15M
Stochastic %K 60%
Beta 1.09
Analysts Sell
Price Target $23.33

Company Profile

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on me...

Industry: Health Information Services
Sector: Healthcare
Phone: 661 723 7723
Address:
800 Park Offices Drive, Suite 401, Research Triangle Park, United States
theoptionsplug
theoptionsplug Jan. 21 at 8:46 AM
THINGS TO WATCH, WEDNESDAY, 1/21/26 👁️ $JNJ $SLP $SCHW $KMI
0 · Reply
NVDAMillionaire
NVDAMillionaire Jan. 20 at 5:32 PM
$SLP Great piece that accurately captures SLP's current position. So if you want to refresh your understanding of SLP or learn about SLP for the first time, this is essential reading. https://everyticker.com/quote/SLP/analysis/simulations-plus-software-resilience-meets-services-reset-in-model-informed-drug-development-nasdaq-slp
0 · Reply
NVDAMillionaire
NVDAMillionaire Jan. 20 at 7:20 AM
$SLP Outstanding article that hits the mark on SLP's current state. So if you want to refresh your SLP insights or learn about SLP from scratch, this is a must read. https://everyticker.com/quote/SLP/analysis/simulations-plus-software-resilience-meets-services-reset-in-model-informed-drug-development-nasdaq-slp
0 · Reply
StockScanners
StockScanners Jan. 10 at 4:13 AM
$SLP keep watch if this holds above 19
0 · Reply
_TylerDurden_
_TylerDurden_ Jan. 9 at 3:17 PM
$SLP AI will replace everything this company offers on a long enough timeline. Dead value prop.
0 · Reply
Bazzzigar
Bazzzigar Jan. 9 at 12:59 PM
$SLP JUNK
0 · Reply
ZacksResearch
ZacksResearch Jan. 9 at 12:27 PM
$SLP just got hit hard after earnings — but is the selloff telling the full story? ⚠️ Q1 fiscal 2026 EPS missed as software revenue fell 17%, pressured by industry headwinds. That said, services momentum and strong bookings are supporting confidence for the rest of fiscal 2026. Is this a temporary stumble or a deeper issue? Full details here 👉 https://www.zacks.com/stock/news/2814771/slp-stock-crashes-on-q1-earnings-miss-software-headwinds-hurt-sales?cid=sm-stocktwits-2-2814771-teaser-28135&ADID=SYND_STOCKTWITS_TWEET_2_2814771_TEASER_28135
0 · Reply
ZacksResearch
ZacksResearch Jan. 9 at 11:27 AM
$SLP shares plunged 5% after missing earnings estimates! 🚨 Q1 EPS fell short by 27.8%, and software revenue dropped 17% YoY amid strong service momentum. Management remains optimistic with forecasts of up to 4% revenue growth for FY26, supported by strong bookings, annual software price increases, and favorable market dynamics. Full breakdown here 👇 https://www.zacks.com/stock/news/2814771/slp-stock-crashes-on-q1-earnings-miss-software-headwinds-hurt-sales?cid=sm-stocktwits-2-2814771-body-28134&ADID=SYND_STOCKTWITS_TWEET_2_2814771_BODY_28134
0 · Reply
_TylerDurden_
_TylerDurden_ Jan. 9 at 2:03 AM
$SLP https://www.marketbeat.com/instant-alerts/simulations-plus-nasdaqslp-announces-quarterly-earnings-results-misses-expectations-by-006-eps-2026-01-08/
0 · Reply
Dieseld28
Dieseld28 Jan. 8 at 9:07 PM
0 · Reply
Latest News on SLP
Simulations Plus, Inc. (SLP) Analyst/Investor Day Transcript

Jan 21, 2026, 8:16 PM EST - 5 days ago

Simulations Plus, Inc. (SLP) Analyst/Investor Day Transcript


Simulations Plus, Inc. (SLP) Q1 2026 Earnings Call Transcript

Jan 8, 2026, 7:54 PM EST - 18 days ago

Simulations Plus, Inc. (SLP) Q1 2026 Earnings Call Transcript


Simulations Plus: Buying On Long-Term Silico Drug-Development

Dec 2, 2025, 9:41 PM EST - 7 weeks ago

Simulations Plus: Buying On Long-Term Silico Drug-Development


Simulations Plus, Inc. (SLP) Q4 2025 Earnings Call Transcript

Dec 1, 2025, 8:13 PM EST - 2 months ago

Simulations Plus, Inc. (SLP) Q4 2025 Earnings Call Transcript


Simulations Plus to Participate in Upcoming Investor Conferences

Aug 27, 2025, 7:50 AM EDT - 5 months ago

Simulations Plus to Participate in Upcoming Investor Conferences


theoptionsplug
theoptionsplug Jan. 21 at 8:46 AM
THINGS TO WATCH, WEDNESDAY, 1/21/26 👁️ $JNJ $SLP $SCHW $KMI
0 · Reply
NVDAMillionaire
NVDAMillionaire Jan. 20 at 5:32 PM
$SLP Great piece that accurately captures SLP's current position. So if you want to refresh your understanding of SLP or learn about SLP for the first time, this is essential reading. https://everyticker.com/quote/SLP/analysis/simulations-plus-software-resilience-meets-services-reset-in-model-informed-drug-development-nasdaq-slp
0 · Reply
NVDAMillionaire
NVDAMillionaire Jan. 20 at 7:20 AM
$SLP Outstanding article that hits the mark on SLP's current state. So if you want to refresh your SLP insights or learn about SLP from scratch, this is a must read. https://everyticker.com/quote/SLP/analysis/simulations-plus-software-resilience-meets-services-reset-in-model-informed-drug-development-nasdaq-slp
0 · Reply
StockScanners
StockScanners Jan. 10 at 4:13 AM
$SLP keep watch if this holds above 19
0 · Reply
_TylerDurden_
_TylerDurden_ Jan. 9 at 3:17 PM
$SLP AI will replace everything this company offers on a long enough timeline. Dead value prop.
0 · Reply
Bazzzigar
Bazzzigar Jan. 9 at 12:59 PM
$SLP JUNK
0 · Reply
ZacksResearch
ZacksResearch Jan. 9 at 12:27 PM
$SLP just got hit hard after earnings — but is the selloff telling the full story? ⚠️ Q1 fiscal 2026 EPS missed as software revenue fell 17%, pressured by industry headwinds. That said, services momentum and strong bookings are supporting confidence for the rest of fiscal 2026. Is this a temporary stumble or a deeper issue? Full details here 👉 https://www.zacks.com/stock/news/2814771/slp-stock-crashes-on-q1-earnings-miss-software-headwinds-hurt-sales?cid=sm-stocktwits-2-2814771-teaser-28135&ADID=SYND_STOCKTWITS_TWEET_2_2814771_TEASER_28135
0 · Reply
ZacksResearch
ZacksResearch Jan. 9 at 11:27 AM
$SLP shares plunged 5% after missing earnings estimates! 🚨 Q1 EPS fell short by 27.8%, and software revenue dropped 17% YoY amid strong service momentum. Management remains optimistic with forecasts of up to 4% revenue growth for FY26, supported by strong bookings, annual software price increases, and favorable market dynamics. Full breakdown here 👇 https://www.zacks.com/stock/news/2814771/slp-stock-crashes-on-q1-earnings-miss-software-headwinds-hurt-sales?cid=sm-stocktwits-2-2814771-body-28134&ADID=SYND_STOCKTWITS_TWEET_2_2814771_BODY_28134
0 · Reply
_TylerDurden_
_TylerDurden_ Jan. 9 at 2:03 AM
$SLP https://www.marketbeat.com/instant-alerts/simulations-plus-nasdaqslp-announces-quarterly-earnings-results-misses-expectations-by-006-eps-2026-01-08/
0 · Reply
Dieseld28
Dieseld28 Jan. 8 at 9:07 PM
0 · Reply
Stocktwits
Stocktwits Jan. 8 at 8:54 PM
$TLRY, $WDFC, $AEHR, $SLP, and $GBX report earnings after the bell today
0 · Reply
eWhispers
eWhispers Jan. 8 at 5:49 PM
#earnings after the close on Thursday, January 8, 2026, with no companies scheduled before the open on Friday, January 9, 2026 https://www.earningswhispers.com/calendar $TLRY $WDFC $AEHR $SLP $GBX
0 · Reply
IN0V8
IN0V8 Jan. 8 at 5:22 PM
$SLP TD Cowen raises target price to $19 from $16
0 · Reply
OpenOutcrier
OpenOutcrier Jan. 8 at 1:50 PM
Top Earnings Th 1/8 Aft: $AEHR $GBX $SLP $TLRY $WDFC . Top Earnings Fri 1/9 Pre: None
0 · Reply
TwoToesTrading
TwoToesTrading Jan. 8 at 1:10 PM
$AEHR $TLRY $WDFC $GBX $SLP Implied moves for this afternoon ER fyi
0 · Reply
trading_momentum_x
trading_momentum_x Jan. 5 at 3:59 AM
ER run up play this week. $SLP Simulations Plus, Inc. (NASDAQ: SLP) is a U.S.-based software and services company that provides modeling and simulation tools for pharmaceutical research and development. Headquartered in Lancaster, California, its platforms are used to predict drug behavior, optimize dosing, and support regulatory submissions. The company serves pharmaceutical companies, biotech firms, and regulatory agencies worldwide. Buy: $17.62 Sell: $19.00 Stoploss: $16.75 Chart:
0 · Reply
RenewableRexV3
RenewableRexV3 Dec. 26 at 4:40 PM
$SLP Risk appetite is present but conditioned on validation. Balance sheet resilience remains an underappreciated swing factor. Sustained traction could validate the investment case. Stronger outcomes appear only when priorities stay focused.
1 · Reply
JarvisFlow
JarvisFlow Dec. 18 at 12:16 PM
BTIG updates rating for Simulations Plus ( $SLP ) to Neutral.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 11 at 5:05 PM
$SLP Share Price: $20.01 Contract Selected: Jun 18, 2026 $20 Calls Buy Zone: $1.70 – $2.10 Target Zone: $3.04 – $3.71 Potential Upside: 69% ROI Time to Expiration: 188 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Godwins26
Godwins26 Dec. 2 at 9:34 PM
2nd Watchlist for today 😊 $PLRZ it's going to $10 $SMX $THH $TMC $SLP
1 · Reply
topstockalerts
topstockalerts Dec. 2 at 5:00 PM
$SLP Looking good!
0 · Reply
d_risk
d_risk Dec. 2 at 3:50 PM
$SLP - Simulations Plus Inc. Common Stock - 10K - Updated Risk Factors SLP’s 2025 10-K risk factors clarify “clients” over “customers,” sharpen focus on model-informed drug development, highlight AI/ML as both a competitive and legal risk, expand on pricing and demand pressures, detail new government grant and shutdown risks, and note recent share repurchase volatility—no major shifts, but more specificity and new AI, grant, and shutdown disclosures. #ModelInformedDrugDevelopment #ShareRepurchaseVolatility #GovernmentGrants #PricingPressure #AIMLRisks 🟢 Added 🟠 Removed https://d-risk.ai/SLP/10-K/2025-12-01
0 · Reply